Drug Approval | November 26, 2025
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
A key highlight will be Brenntag’s qualified amino acids portfolio
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival
Jaypirca is making waves in the fight against B-cell malignancies
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
Subscribe To Our Newsletter & Stay Updated
